

CORRIGENDUM

Clarification: Whole-organ transdermal photobiomodulation (PBM) of COVID-19: A 50-patient case study

Richard K. Williams¹ | John Raimondo² | David Cahn³ | Aldon Williams⁴ | Daniel Schell⁵

¹Applied BioPhotonics Ltd, Cupertino, California, USA

²Pulmonair, San Antonio, Texas, USA

³O'Connor Hospital, San Jose, California, USA

⁴Advanced Spinal Pain Management, Boerne, Texas, USA

⁵LightMD, Inc, Cupertino, California, USA

A reader of this research article [1] raised concerns about the accuracy of the Conflict of Interest statement.

The authors of this article assert that there was no intent to violate any ethical guidelines or intentionally avoid full disclosure of all conflicts of interest.

This clarification discloses in more detail the positions that the authors hold in their respective companies and their relationships to each other.

CONFLICTS OF INTEREST

Richard K. Williams is founder, CEO, president, CTO, and a shareholder of Applied BioPhotonics, Ltd. (ABP) and co-founder and CEO of LightMD, Inc., a member of the ABP group of global affiliates. He is also founder, CEO, and CTO of technology-innovator Adventive Technology Ltd., and a founding member of HyperSphere.ai and several blockchain DAOs. ABP is a GMP-certified device manufacturer, system specifier, and IP holder of medical devices and PBM therapy products.

Daniel Schell is co-founder and president of LightMD, Inc. and a minority shareholder of ABP. Mr. Schell is not an employee of ABP. LightMD, Inc. is a US FDA-registered, licensed importer and distributor of ABP products in the United States.

Dr. John Raimondo, Dr. David Cahn, and Dr. Aldon Williams are independently operating licensed physicians and not service providers for either company. They are not shareholders, employees or paid consultants of either LightMD or ABP and received no compensation for their involvement in performing this study. Any other doctors who assisted in this study also received no compensation. No patients were paid or charged for receiving PBM therapy in this study. No patients requesting therapy were turned away from receiving treatments.

REFERENCE

[1] R. K. Williams, J. Raimondo, D. Cahn, A. Williams, D. Schell, *J. Biophotonics* **2021**, e202100194. <https://doi.org/https://doi.org/10.1002/jbio.202100194>